Molecular Background of miRNA Role in Asthma and COPD: An Updated Insight

Szymczak, Izabela; Wieczfińska, Joanna; Pawliczak, Rafał

doi:10.1155/2016/7802521

Cited by 44 publications

(36 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Different papers have recently demonstrated that some miRNAs are elevated in asthma and COPD patients 16. Moreover, the expression of miRNAs seems to be different in various asthma models.…”

Section: Discussionmentioning

confidence: 99%

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype

Lacedonia

Palladino

Barbaro

et al. 2017

COPD

View full text Add to dashboard Cite

Background and objectivesA new phenotype with overlapping characteristics between asthma and chronic obstructive pulmonary disease (COPD) called asthma–COPD overlap syndrome (ACOS) is emerging among inflammation diseases. To date, there is no agreement on specific criteria to define this syndrome, and the current guidelines are insufficient to classify the analogy and differences between overlap and COPD or asthma phenotypes. It would be necessary to identify new biomarkers able to identify these diseases clearly. Thus, the aim of this study was to identify a serum and supernatant of sputum microRNA (miRNA) expression profile of miRNA-145 and miRNA-338 in patients with asthma (n=13), COPD (n=31), and ACOS (n=8) and controls (n=7).MethodsThe expression was evaluated using quantitative real-time polymerase chain reaction (qRT-PCR). For statistical analysis, the ANOVA test, Kruskal–Wallis test, Mann–Whitney U-test, and Spearman’s rank correlation were used.ResultsThe main finding of this work is that the expression of miRNA-338 is higher in the supernatant of different obstructive diseases than in peripheral blood, while miRNA-145 is higher only in the supernatant of asthma patients. The expression of both selected miRNAs is higher in the supernatant of asthma and COPD patients than in controls.ConclusionDifferences in sputum miRNA expression profile were observed between patients with ACOS and asthma or COPD, which underline the potential role of miRNA as a biomarker that is able to discriminate patients with ACOS, asthma, and COPD.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype

Lacedonia

Palladino

Barbaro

et al. 2017

COPD

View full text Add to dashboard Cite

show abstract

“…This disease is accompanied by the presence of chronic obstruction. [ 1 ] Multiple lines of evidence have indicated that a wide range of factors (i.e., genetical and environmental) are involved in the initiation and progression of COPD. Smoking is known as one of the main factors which could be associated with chronic inflammation of the airways.…”

Section: Introductionmentioning

confidence: 99%

Chronic obstructive pulmonary disease: MicroRNAs and exosomes as new diagnostic and therapeutic biomarkers

et al. 2018

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is known as a progressive lung disease and the fourth leading cause of death worldwide. Despite valuable efforts, there is still no accurate diagnostic and prognostic tool for COPD. Hence, it seems that finding new biomarkers could contribute to provide better therapeutic platforms for COPD patients. Among various biomarkers, microRNAs (miRNAs) have emerged as new biomarkers for the prognosis and diagnosis of patients with COPD. It has been shown that deregulation of miRNAs targeting a variety of cellular and molecular pathways such as Notch, Wnt, hypoxia-inducible factor-1α, transforming growth factor, Kras, and Smad could be involved in COPD pathogenesis. Multiple lines of evidence have indicated that extracellular vesicles such as exosomes could carry a variety of cargos (i.e., mRNAs, miRNAs, and proteins) which transfer various cellular and molecular signals to recipient cells. Here, we summarized various miRNAs which could be applied as diagnostic and prognostic biomarkers in the treatment of patients with COPD. Moreover, we highlighted the role of extracellular vesicles containing miRNAs as diagnostic and prognostic biomarkers in COPD patients.

show abstract

“…Lowering GSL levels in mast cells in an animal model of asthma was found to ameliorate disease manifestations [ 45 ]. Both mature forms of miR-499a and miR-499b were predicted to target about 40 and 60 genes in TGF-beta and TNF signaling pathways, important mediators contributing in lung tissue fibrosis and proliferation of smooth muscle cells with subsequent airway remodeling [ 46 ]. We also identified several targets for miR-499 gene family in adherence junction and focal adhesion pathways.…”

Section: Discussionmentioning

confidence: 99%

Structure and functional impact of seed region variant in MIR-499 gene family in bronchial asthma

Toraih¹,

Hussein²,

Ageeli³

et al. 2017

Respir Res

View full text Add to dashboard Cite

BackgroundSmall non-coding RNAs (microRNAs) have been evolved to master numerous cellular processes. Genetic variants within microRNA seed region might influence microRNA biogenesis and function. The study aimed at determining the role of microRNA-499 (MIR-499) gene family polymorphism as a marker for susceptibility and progression of bronchial asthma and to analyze the structural and functional impact of rs3746444 within the seed region.MethodsGenotyping for 192 participants (96 patients and 96 controls) in the discovery phase and 319 subjects (115 patients and 204 controls) in the replication phase was performed via Real Time-Polymerase Chain Reaction technology. Patients underwent the methacholine challenge test and biochemical analysis. Gene structural and functional analysis, target prediction, annotation clustering, and pathway enrichment analysis were executed. Predicted functional effect of rs37464443 SNP was analyzed.ResultsmiR-499 gene family is highly implicated in inflammation-related signaling pathways. Rs374644 (A > G) in MIR499A and MIR499B within the seed region could disrupt target genes and create new genes. The G variant was associated with high risk of developing asthma under all genetic association models (G versus A: OR = 3.27, 95% CI = 2.53–4.22; GG versus AA: OR = 9.52, 95% CI = 5.61–16.5; AG versus AA: OR = 2.13, 95% CI = 1.24–3.46; GG + AG versus AA: OR = 4.43, 95% CI = 2.88–6.82). GG genotype was associated with poor pre-bronchodilator FEV1 (p = 0.047) and the worst bronchodilator response after Salbutamol inhalation, represented in low peaked expiratory flow rate (p = 0.035).ConclusionsmiR-499 rs3746444 (A > G) polymorphism was associated with asthma susceptibility and bronchodilator response in Egyptian children and adolescents. Further functional analysis is warranted to develop more specific theranostic agents for selecting targeted therapy.Electronic supplementary materialThe online version of this article (10.1186/s12931-017-0648-0) contains supplementary material, which is available to authorized users.

show abstract

Molecular Background of miRNA Role in Asthma and COPD: An Updated Insight

Cited by 44 publications

References 89 publications

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype

Chronic obstructive pulmonary disease: MicroRNAs and exosomes as new diagnostic and therapeutic biomarkers

Structure and functional impact of seed region variant in MIR-499 gene family in bronchial asthma

Contact Info

Product

Resources

About

Molecular Background of miRNA Role in Asthma and COPD: An Updated Insight

Cited by 44 publications

References 89 publications

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma&ndash;COPD overlap syndrome phenotype

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma&ndash;COPD overlap syndrome phenotype

Chronic obstructive pulmonary disease: MicroRNAs and exosomes as new diagnostic and therapeutic biomarkers

Structure and functional impact of seed region variant in MIR-499 gene family in bronchial asthma

Contact Info

Product

Resources

About

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype